title: Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7.
authors.forename: Björn
authors.initials: B
authors.lastname: Rüter
authors.forename: Pierre
authors.initials: P
authors.lastname: Wijermans
authors.forename: Rainer
authors.initials: R
authors.lastname: Claus
authors.forename: Regina
authors.initials: R
authors.lastname: Kunzmann
authors.forename: Michael
authors.initials: M
authors.lastname: Lübbert
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D001374:Azacitidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D002897:Chromosomes, Human, Pair 7; D000077209:Decitabine; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D007958:Leukocyte Count; D009006:Monosomy; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D000077209:Decitabine; D001374:Azacitidine